Betul Yilmaz Furtun

Dr. Betul Yilmaz Furtun

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2025 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
BFBetul Yilmaz Furtun
Betul Yilmaz Furtun
MTMira K. Trivedi
Mira K. Trivedi
PDPatrick Day
Patrick Day
PKPamela Ketawaroo
Pamela Ketawaroo
MMMichelle Mathevosian
Michelle Mathevosian
SMShaine Alaine Morris
Shaine Alaine Morris
BACKGROUND: Infants with hypoplastic left heart syndrome with severely restrictive or intact atrial septum (R/IAS) have low survival. In-utero creation of an atrial septal communication has been reported, with high complication rates. METHODS: We performed a retrospective cohort study of fetuses with hypoplastic left heart syndrome, double outlet right ventricular with mitral stenosis/atresia, or mitral valve dysplasia and R/IAS from 2012 to 2024 who underwent evaluation for fetal atrial septal intervention (FASI). Excluding those with comorbidities limiting candidacy, discharge survival and overall survival were compared between (1) those undergoing and not undergoing FASI, and (2) those undergoing technically successful FASI (TS-FASI) and all others. RESULTS: Of 60 fetuses with R/IAS, 18 were considered extremely high risk and excluded from analysis. Among the remaining 42, 25 underwent FASI and 17 did not, with no significant baseline echocardiographic differences. FASI was technically successful in 18 cases, with 13 survivors (6 post-Glenn, 6 post-Fontan, 1 post-Ross). In the 7 unsuccessful FASIs, there were 5 peri-procedural deaths and 1 fetal demise that occurred post-FASI. Technical success rates improved from 58% (first 12) to 85% (last 13). Of 20 FASI patients with fetal magnetic resonance imaging, 15 (75%) had nutmeg lung ; of the 9 with nutmeg lung and post-TS-FASI fetal magnetic resonance imaging, 8 improved. Survival to discharge and overall survival were 52% in the FASI group versus 29% in the non-FASI group ( P =0.147 and log-rank P =0.376, respectively). When comparing TS-FASI to all others, survival was higher (72.2% versus 20.8% for discharge and overall survival, P =0.001 and log-rank P <0.001, respectively). All TS-FASI survivors with catheterization data (11/13) had PVR <3 Woods units before Glenn/Fontan. CONCLUSIONS: In our cohort, fetuses with R/IAS post-TS-FASI had significantly higher discharge and overall survival rates compared with all other fetuses with R/IAS. Nutmeg lung improved in the majority of TS-FASI cases with post-FASI imaging.

BFBetul Yilmaz Furtun
Betul Yilmaz Furtun
SMShaine Alaine Morris
Shaine Alaine Morris
Fetal cardiac intervention (FCI) is an emerging and rapidly advancing group of interventions designed to improve outcomes for fetuses with cardiovascular disease. Currently, FCI is comprised of pharmacologic therapies (e.g., trans-placental antiarrhythmics for fetal arrhythmia), open surgical procedures (e.g., surgical resection of pericardial teratoma), and catheter-based procedures (e.g., fetal aortic valvuloplasty for aortic stenosis). This review focuses on the rationale, criteria for inclusion, technical details, and current outcomes of the three most frequently performed catheter-based FCI procedures: (1) aortic valvuloplasty for critical aortic stenosis (AS) associated with evolving hypoplastic left heart syndrome (HLHS), (2) atrial septal intervention for HLHS with severely restrictive or intact atrial septum (R/IAS), and (3) pulmonary valvuloplasty for pulmonary atresia with intact ventricular septum (PA/IVS).

17 September 2024 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Closed access
BFBetul Yilmaz Furtun
Betul Yilmaz Furtun
AQA. M. Qureshi
A. M. Qureshi
TNT. Niaz
T. Niaz
CSC. D. Sutton
C. D. Sutton
MCM. Sanz Cortes
M. Sanz Cortes
TTthe Texas Children's Hospital Fetal Cardiac Intervention Team
the Texas Children's Hospital Fetal Cardiac Intervention Team

24 June 2023 in European Journal of Therapeutics
Verified
Journal Article
Open access
PDF file
ABAyşe Balat
Ayşe Balat
ŞEŞevki Eren
Şevki Eren
MMMehmet Sait Menzilcioğlu
Mehmet Sait Menzilcioğlu
IBIlhan Bahşi
Ilhan Bahşi
Ilkay DOGANIlkay DOGAN
Ilkay DOGAN
JSJoseph Schmidt
Joseph Schmidt
Dear Colleagues, In the previous editorial paper published by Balat et al. [1] as an Early View Article a few months ago, it was reported that there were changes in the Editorial Team of the European Journal of Therapeutics (Eur J Ther). During these few months, while the preparations for the new issue (June 2023, volume 29, Issue 2) continued, the editorial board also was revised. We would like to inform you that the Editorial Board has been strengthened by academics who are competent in their fields from many countries of the world and will continue to be strengthened in the future. As it is known, Eur J Ther started broadcasting in 1990 as a Journal of the Faculty of Medicine University of Gaziantep (In Turkish: Gaziantep Üniversitesi Tıp Fakültesi Dergisi). In the first paper titled “While Starting” (In Turkish: Başlarken) of the first issue, Prof. Sabri Güngör, who was the first Editor-in-Chief, stated that the aim of the journal is to have an influential place in the field of science [2]. Over the past three decades, the journal has continued to advance. At the present time, it is inevitable to reorganise the editorial board of the journal and enrich it with leading international editors in order to move the journal to better places. This editorial will explain essential developments in the journal in the last few months, and the new Editorial Board Members of the Eur J Ther will be introduced. Changes are inevitable, and we are delighted to announce that this issue marks several significant improvements. Specifically, we bolstered our editorial team with esteemed international academics and expanded our pool of referees. Consequently, the evaluation period for the submitted articles was significantly reduced. In the last two months, the journal metrics are as follows: Acceptance rate: %29 Average time until the final decision: 24.4 days Average time to publish as Accepted/Early View Article, after acceptance: 4.8 days. Thanks to these improvements, as you will notice, there are 25 articles in this issue. In this way, this issue has been the issue in which most articles have been published so far. In addition, applications were made to DOAJ (Directory of Open Access Journals) and BASE (Bielefeld Academic Search Engine), among the most essential open-access databases in the world, in May 2023. Moreover, cited references to the previous and/or alternative names of the journal (Gaziantep Medical Journal, Gaziantep Med J, Gaziantep Tıp Dergisi and Gaziantep Üniversitesi Tıp Fakültesi Dergisi) in Web of Science that were not reflected in the journal metrics were identified and reported to the Web of Science. Some of these correction requests have been finalized and corrected, and thus the total number of citations and the H-index of the journal increased [3]. After all these data are updated, it will be seen that the citation values of the Eur J Ther will increase even more. We will also update the guidelines for the authors and reviewers with respect to the ICMJE [4] and EQUATOR Network [5], which will enhance the quality of research in the medical fraternity. Additionally, the use of DOI for articles published in the journal started in 2011 (2011, volume 17, Issue 2). In order to facilitate the recognition and access of the articles, DOIs have also been defined for all articles published in previous issues. Editors Ayşe Balat, MD, became the new Editor-in-Chief of Eur J Ther for the second time, the first between 2007-2010. She is a Professor in Pediatrics and a specialist in Pediatric Nephrology and Rheumatology. She has been working as Vice President of Gaziantep University since October 2020. She was the Dean of Gaziantep University Medical Faculty (2007-2010), President of the Mediterranean Kidney Society (MKS) between 2015 to 2018, and Secretary beginning in 2018. She is also President of the International Association for the History of Nephrology (IAHN) since 2022. In Gaziantep, she first established Pediatric Nephrology and Pediatric Rheumatology Units, and the first peritoneal dialysis was performed by her. She has several studies published in international and national peer-reviewed scientific journals (H-Index: 26, i10-index: 59 and approximately 2500 citations). She was the Guest Editor of the International Journal of Nephrology in 2012 (special issue titled “Devil’s Triangle in Kidney Diseases: Oxidative Stress, Mediators, and Inflammation”). She is a member of many national and international associations related to her field, including membership in the Turkish Pediatric Nephrology Association board in the past. She has several scientific presentation awards at national and international congresses. She has been joined as an “invited speaker” at 20 International Meetings. As of 2007, she organizes World Kidney Day activities within the scope of the “Survival is not Enough” program (in the first rank among European pediatric nephrologists as an organizer of those activities). Recently, she was elected as a “lifelong member of the Academy of Medicine and Surgical Sciences” of the University of Naples, which is one of the four important academies in Naples. Şevki Hakan Eren, MD, is the new Deputy Editor-in-Chief of the Eur J Ther. Dr Eren graduated from the Medical School, University of Gaziantep, Turkey and completed Emergency training at Cumhuriyet University. He has been working as a Professor at Gaziantep University, Department of Emergency Medicine, Gaziantep, Turkey. He is interested in traumatology, and toxicology. Mehmet Sait Menzilcioğlu, MD, is the new Deputy Editor-in-Chief of the Eur J Ther. Dr. Menzilcioğlu graduated from the Medical School, University of Gaziantep, Turkey and completed Radiology training at the same University. He has been working as an Associate Professor at Gaziantep University, Department of Radiology,...

6 January 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
SMShiraz A. Maskatia
Shiraz A. Maskatia
FCFu-Sheng Chou
Fu-Sheng Chou
BFBetul Yilmaz Furtun
Betul Yilmaz Furtun
LHLisa Howley
Lisa Howley
VAVidhya Annavajjhala
Vidhya Annavajjhala
AMAnita J. Moon‐Grady
Anita J. Moon‐Grady
Background: Current models to predict outcomes in advanced twin–twin transfusion syndrome are limited. We hypothesized that twin and cotwin echocardiographic factors would improve model performance for donor and recipient demise following laser photocoagulation therapy. Methods: We performed a multicenter retrospective cohort study of stage 3 to 4 twin–twin transfusion syndrome referred for laser photocoagulation therapy. Fetal echocardiograms were analyzed at a core laboratory. We used multivariable logistic regression models to select variables used for generalized linear mixed‐effects modeling. Separate models were developed for donor and recipient demise, using both twin and cotwin variables. Models were assessed by area under the receiver operating characteristic curves. Results: Laser photocoagulation therapy was performed in 285 twin gestations at 20.2±2.8 weeks. Donor demise (32%) occurred more frequently than recipient demise (15%; P <0.001). Final model variables for donor demise were donor fetal weight, nifedipine administration, umbilical arterial and venous flow patterns, donor cardiac output, left ventricular myocardial performance index, recipient deepest vertical pocket, recipient chest/thoracic ratio, recipient cardiac output, and recipient ductus venosus flow pattern; and for recipient demise were nifedipine use, recipient combined cardiac output, recipient left ventricular myocardial performance index, recipient umbilical arterial flow pattern, and donor left ventricular myocardial performance index. Including cotwin variables in models for donor and recipient demise improved performance. Final model area under the receiver operating characteristic curves were 0.82 for both donor and recipient demise. Conclusions: This is the largest multicenter study to rigorously evaluate echocardiographic metrics associated with fetal demise in twin–twin transfusion syndrome and the first to identify intertwin parameters associated with cotwin demise.

5 August 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
BFBetul Yilmaz Furtun
Betul Yilmaz Furtun
KPKavitha Pundi
Kavitha Pundi
AMAnita Moon‐Grady
Anita Moon‐Grady
NCNicole Cresalia
Nicole Cresalia
ANAsela Nieuwsma
Asela Nieuwsma
SMShaine Alaine Morris
Shaine Alaine Morris
Background: Case series report high mortality after fetal diagnosis of moderate to severe mitral regurgitation in combination with left atrial dilation, hydrops, or restrictive atrial septum. However, overall outcomes and specific high‐risk features remain unclear. Methods: We performed a multicenter retrospective cohort study of fetuses with ≥moderate mitral regurgitation and normal cardiac connections evaluated January 1, 2005 to January 31, 2016. Fetuses undergoing fetal cardiac intervention (FCI) were described separately. We assessed associations between fetal echocardiographic features and discharge mortality using mixed logistic regression and classification and regression tree modeling, stratified by studies performed <28 and ≥28 weeks gestational age (GA). Results: Of 67 fetuses, 96% had aortic valve stenosis or atresia. Among the non‐FCI group, fetal and discharge mortality was 10% (5/51) and 55% (28/51), respectively. For echocardiograms performed <28 weeks GA, only restrictive atrial septum (odds ratio [OR], 49.6 [95% CI, 5.6–437.5]) and earlier GA at referral (OR 0.72 per increasing week GA [95% CI 0.54–0.96]) remained associated in multivariable analysis. For those ≥28 weeks GA, in multivariable analysis, left atrial dilation (OR, 12.41 [95% CI, 2.19–70.33]) and lower ascending aortic Z score (OR per 1 unit increase, 0.61 [95% CI, 0.39–0.94]) remained in the model. By classification and regression tree modeling, left atrial dilation, restrictive atrial septum, and ascending aortic Z score <−1.3 were the key discriminators between survivors and nonsurvivors. Most FCIs were aortic valvuloplasty (13/16). Discharge mortality among FCI fetuses was 38%, not significantly different from non‐FCI once adjusting for mitral regurgitation and LA dilation. Conclusions: Fetal ≥moderate MsR is associated with high mortality. Left atrial dilation, restrictive atrial septum, and smaller ascending aorta confer highest risk for mortality.